ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07609446 (Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma: A Prospective, Multicenter, Phase II Study
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.Cancers · 2026Guideline
- CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis.Frontiers in immunology · 2025Pooled it
- [Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Guideline
- Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.Oncoimmunology · 2026Trial
- Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.British journal of haematology · 2026Trial
- Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.JAMA oncology · 2026Trial
- A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.Blood advances · 2025Trial
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.Blood advances · 2025Trial
- Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.Nature communications · 2025Trial
- Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.Blood advances · 2025Trial
- Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.Signal transduction and targeted therapy · 2025Trial
- Trial
- Article
- Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.HemaSphere · 2026Article
- Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.Antibodies (Basel, Switzerland) · 2026Article
- Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.Blood cancer journal · 2026Article
- Towards a chemo-free approach for follicular lymphoma.British journal of haematology · 2025Review
- Current landscape of frontline and relapsed follicular lymphoma trials.Blood neoplasia · 2025Review
- A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances.The Korean journal of internal medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 7 countries.
Franck MorschhauserUniversity of Lille, CHU Lille, Lille, France.ORCID 0000-0002-3714-9824
Loretta NastoupilThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6071-8610
Pierre FeugierNancy University Hospital, Vandoeuvre-lès-Nancy, France.
Jean-Marc Schiano de ColellaInstitut Paoli Calmettes, CRCM, AMU, Marseille, France.ORCID 0000-0001-9923-4808
Hervé TillyCentre Henri Becquerel, Rouen, France.
Maria Lia PalombaMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5099-9156
Emmanuel BachyHospices Civils de Lyon and Claude Bernard Lyon 1 Université, Lyon, France.ORCID 0000-0003-2694-7510
Christophe FruchartCH de Dunkerque, Dunkerque, France.
Edward N LibbyUniversity of Washington, Seattle, WA.
Rene-Olivier CasasnovasCHU Dijon-Bourgogne, Dijon, France.ORCID 0000-0002-1156-8983
Ian W FlinnSarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.ORCID 0000-0001-6724-290X
Corinne HaiounHenri Mondor Université Hôpital, UPEC, Créteil, France.
Hervé MaisonneuveCentre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.
Loic YsebaertInstitut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.ORCID 0000-0003-4102-7261
Nancy L BartlettWashington University School of Medicine, St Louis, MO.ORCID 0000-0001-8470-394X
Kamal BouabdallahBordeaux University Hospital, Bordeaux, France.
Pauline BriceHôpital Saint-Louis, Paris, France.
Vincent RibragInstitut Gustave Roussy, Villejuif, France.
Steven Le GouillInstitut Curie, Paris, France.ORCID 0000-0001-9840-2128
Nicolas DaguindauAnnecy Hôpital, Annecy, France.
Stéphanie GuidezCHU de Poitiers, Poitiers, France.
Gian Matteo PicaCentre Hospitalier Métropole Savoie Chambéry, Chambéry, France.
Alejandro Martín García-SanchoHospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.ORCID 0000-0001-6330-1028
Armondo López-GuillermoHospital Clínic de Barcelona, Barcelona, Spain.ORCID 0000-0002-8588-8381
Jean-François LaroucheCHU de Québec, Québec, Canada.
Kiyoshi AndoTokai University School of Medicine, Kanagawa, Japan.
Maria Gomes da SilvaInstituto Português de Oncologia de Lisboa, Lisboa, Portugal.ORCID 0000-0002-6993-2450
Marc AndréCHU UCL Namur, Yvoir, Belgium.
Wu KalungZNA Stuivenberg, Antwerp, Belgium.ORCID 0000-0001-6042-978X
Laurie H SehnBC Cancer Centre for Lymphoid Cancer, Vancouver, Canada.ORCID 0000-0003-1860-9765
Koji IzutsuNational Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-9129-8057
Guillaume CartronCHU Montpellier, Montpellier, France.ORCID 0000-0003-0659-9635
Argyrios GkasiamisBristol Myers Squibb, Princeton, NJ.
Russell CroweBristol Myers Squibb, Princeton, NJ.
Luc XerriInstitut Paoli Calmettes, CRCM, AMU, Marseille, France.
Nathan H FowlerThe University of Texas MD Anderson Cancer Center, Houston, TX.
Gilles SallesMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9541-8666
Institut Pprime · FRMemorial Sloan Kettering Cancer Center · USPrinceton University · USThe University of Texas MD Anderson Cancer Center · USAssistance Publique – Hôpitaux de Paris · FRCentre Henri BecquerelCentre Hospitalier Annecy Genevois · FRCentre Hospitalier Métropole Savoie · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Poitiers · FRCentre hospitalier universitaire de Québec · CACHU Dijon Bourgogne · FRCHU Dinant Godinne UCL Namur · BEHospital Clínic de Barcelona · ESInstitut Curie · FRInstitut Gustave Roussy · FRInstituto de Investigación Biomédica de Salamanca · ESInstitut universitaire du cancer de Toulouse Oncopole · FR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, FollicularNeoplasms, Second PrimaryAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideRituximabSurvival RateLenalidomideRituximab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07609446ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.